Biopharmaceutical sponsor considerations when selecting a CDMO may include timelines, cost, regulatory requirements, capacity, quality, risks, and previous experience. To help sponsors better understand and prioritize development and manufacturing elements, ISR conducts four annual, manufacturing-specific benchmark studies that ask professionals…
Manufacturing
The past 25 years have seen a steady progression in business relationships between CDMOs and drug developers.
The initial focus of identifying supply chain inefficiencies has advanced from controlling fixed costs and capacity fluctuations to gaining access to specific technologies, skills, and/or scientific expertise not possessed in-house.
Our research helps drug innovators understand the dynamic drug manufacturing environment, identify the right type of outsourcing model to best meet their organizations’ needs, and make smarter CDMO selection decisions based on hard data collected from outsourcing peers.
CDMOs benefit from understanding the competitive landscape, outsourcing drivers, CDMO selection criteria, and the decision-making process. Additionally, our reports provide insight into potential changes in demand for CDMO services and ways service providers could better meet the needs of drug developers.
